16,817 Shares in Ralliant Corporation $RAL Acquired by Canada Pension Plan Investment Board

Key Points

• Canada Pension Plan Investment Board acquired 16,817 Ralliant shares worth approximately $1.24 million during the second quarter. Other major investors, including BlackRock, Viking Global Investors and State Street, also initiated sizable positions.
• Analyst sentiment is generally positive, with Ralliant holding a “Moderate Buy” consensus rating and an average price target of $75.70. The company exceeded quarterly earnings expectations, reporting $0.68 in EPS versus the $0.63 consensus estimate.
• Ralliant shares opened at $61.55, down 0.3%, while CEO Tamara Newcombe and SVP Karen Bick sold shares under pre-arranged trading plans. The company also declared a quarterly dividend of $0.05 per share, representing a 0.3% annualized yield.

Canada Pension Plan Investment Board bought a new stake in Ralliant Corporation (NYSE:RAL - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 16,817 shares of the company's stock, valued at approximately $1,238,000.

Several other hedge funds have also recently added to or reduced their stakes in RAL. BlackRock Inc. bought a new position in shares of Ralliant in the second quarter worth $1,039,481,000. Viking Global Investors LP bought a new stake in shares of Ralliant during the second quarter valued at about $257,200,000. State Street Corp bought a new stake in shares of Ralliant during the second quarter valued at about $213,096,000. Millennium Management LLC lifted its holdings in Ralliant by 172.4% in the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company's stock worth $253,175,000 after purchasing an additional 3,147,660 shares during the period. Finally, Flossbach Von Storch SE acquired a new stake in Ralliant in the second quarter worth about $222,460,000.

Wall Street Analyst Weigh In

Several research firms have commented on RAL. Evercore initiated coverage on shares of Ralliant in a research note on Tuesday, June 9th. They set an "outperform" rating and a $80.00 target price on the stock. Truist Financial reaffirmed a "buy" rating and issued a $82.00 price target (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. Royal Bank Of Canada upped their price target on shares of Ralliant from $71.00 to $73.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. Weiss Ratings reiterated a "sell (d)" rating on shares of Ralliant in a report on Friday, July 31st. Finally, TD Cowen raised their price objective on shares of Ralliant from $70.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Ralliant presently has an average rating of "Moderate Buy" and a consensus target price of $75.70.

Insider Activity

In related news, SVP Karen M. Bick sold 6,062 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $72.00, for a total value of $436,464.00. Following the sale, the senior vice president directly owned 31,668 shares in the company, valued at $2,280,096. The trade was a 16.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the business's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the completion of the sale, the chief executive officer owned 251,967 shares in the company, valued at $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.42% of the company's stock.

Ralliant Stock Down 0.3%

RAL opened at $61.55 on Tuesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. The company has a market capitalization of $6.81 billion, a PE ratio of -5.67, a P/E/G ratio of 2.29 and a beta of 1.61. The stock's fifty day moving average is $68.28 and its 200-day moving average is $56.66. Ralliant Corporation has a one year low of $37.27 and a one year high of $75.41.

Ralliant (NYSE:RAL - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.05. The business had revenue of $567.80 million during the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities analysts predict that Ralliant Corporation will post 2.87 EPS for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant's dividend payout ratio is presently -1.84%.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source